Key Highlights
- 12.9 percent was the one-day drop in Spyre Therapeutics (NASDAQ:SYRE) to USD 80.77 on October 6, 2026, after the company launched a public stock offering late on October 5, 2026, according to published market data.
- USD 350 million is the gross size of the offering, 4,117,648 shares at USD 85.00 each, with a 30-day underwriter option for about USD 52.5 million more and an expected closing on October 7, 2026.
- 8.3 percent is the discount of the USD 85.00 Offer Price to the implied prior close of USD 92.72, simple arithmetic on two published numbers, which helps explain why SYRE shares gapped lower.
- SPY072 for hidradenitis suppurativa is the new late-stage program named in the use of proceeds, alongside gastroenterology and rheumatology work, Manufacturing and Phase 3 readiness at Spyre Therapeutics (NASDAQ:SYRE).
Offering Priced at USD 85.00
Spyre announced a proposed underwritten public offering of common stock on October 5, 2026, then priced it at USD 85.00 a share for gross proceeds of about USD 350.0 million, according to the company release. That equals 4,117,648 shares. Underwriters hold a 30-day option to buy up to 15 percent more, about USD 52.5 million at the offer price. Jefferies, TD Cowen, Leerink Partners and Stifel are joint book-running managers, with LifeSci Capital as passive bookrunner. Closing is expected on October 7, 2026, subject to customary conditions. Published market data show Spyre Therapeutics (NASDAQ:SYRE) fell 12.89 percent to USD 80.77 on October 6, 2026, on Volume roughly nine times its average. The registration statement on Form S-3 became effective on June 26, 2026.
Why Offerings Move Biotech Shares
Companies sell new shares at a discount to the last trade so that institutions will absorb a large block quickly. Existing holders then own a smaller slice of the company, and the market often marks the stock down toward the offer price. Biotechs without product Revenue use such raises to fund trials. Spyre says it will use net proceeds for programs in gastroenterology, rheumatology and dermatology, including preclinical studies, clinical trials, manufacturing and Phase 3 readiness, and to move SPY072 into late-stage development for hidradenitis suppurativa. This is the company's second large raise this year. In April 2026 it sold 6.5 million shares at USD 62.00, and its 10-Q showed about USD 741 million of cash on March 31, 2026.
Risks and What to Watch
Dilution is the immediate risk, and the greenshoe could add to it if underwriters exercise the option within 30 days. Late-stage skin disease development is costly, and any trial setback would test the financing logic. Clinical results in inflammatory bowel disease, where the company reported positive Phase 2 SKYLINE data for SPY001 in ulcerative colitis, remain the core valuation driver. Peers in immunology biotech tend to trade on data, not funding, so the next catalysts matter more than this raise. Watch the October 7, 2026 closing, any filing on the option exercise, the lock-up terms in the prospectus supplement, and the company's next Quarterly Report for updated cash and spending guidance.
Where Things Stand
Spyre Therapeutics (NASDAQ:SYRE) fell 12.9 percent because it priced a USD 350 million stock offering at USD 85.00, about 8.3 percent below the implied prior close, and the market quickly repriced the shares for added Supply and dilution. The raise strengthens funding for gastroenterology, rheumatology and the new SPY072 skin disease program, but it does not change the clinical risk. Investors will now track the closing, the option exercise and upcoming trial data.






Please wait processing your request...